Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: Highly active antiretroviral
therapy (HAART) has been shown to substantially decrease mortality among patients
infected with human immunodeficiency virus (HIV).1 However,
treatment guidelines have recently supported initiating HAART later in the
course of HIV infection. This requires that monitoring of CD4 cell counts
be conducted at the time of HIV diagnosis and every 3 months thereafter to
ensure treatment is initiated before patients become vulnerable to opportunistic
infections.1,2 This may
require interventions for populations who may be at risk of poor access to
health care.3 We evaluated rates of CD4
cell count monitoring among users of injection drugs having access to free
HIV/AIDS care and antiretroviral therapy.4
Wood E, Hogg RS, Bonner S, et al. Staging for Antiretroviral Therapy Among HIV-Infected Drug Users. JAMA. 2004;292(10):1175–1177. doi:10.1001/jama.292.10.1175-b
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: